<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01039285</url>
  </required_header>
  <id_info>
    <org_study_id>MRU-09-02</org_study_id>
    <secondary_id>2009-012817-23</secondary_id>
    <nct_id>NCT01039285</nct_id>
  </id_info>
  <brief_title>Exogenous Surfactant in Very Preterm Neonates in Prevention of Bronchopulmonary Dysplasia</brief_title>
  <acronym>CURDYS</acronym>
  <official_title>Exogenous Surfactant in Very Preterm Neonates Presenting With Severe Respiratory Distress in Prevention of Bronchopulmonary Dysplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jean Michel Hascoet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ARAIRLOR</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Maternite Regionale Universitaire</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Advances in perinatal care have made it possible to improve the survival of the most immature
      neonates, but at the cost of an increase in the population at risk of developing
      bronchopulmonary dysplasia (BPD). Measures that have attempted to limit the development of
      BPD are not always effective, or related to major side effects. The physiopathological
      factors that are identified in BPD should, in theory, respond to surfactant. Therefore, the
      use of an exogenous surfactant in neonates presenting with pulmonary disease requiring
      mechanical ventilation, leading to a significant risk of BPD, should allow earlier extubation
      and thus promote pulmonary healing and growth.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 2009</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>duration of assisted ventilation</measure>
    <time_frame>days</time_frame>
    <description>we aim to demonstrate a significant reduction in the duration of assisted ventilation in children presenting with severe respiratory distress at 14+/-2 days of life.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>to reduce the incidence of BPD</measure>
    <time_frame>36 weeks post conceptional age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to improve the inflammatory status of the lung and to restore its capacities for healing and growth</measure>
    <time_frame>one month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to improve development in stature and weight, psychomotor development, and to reduce respiratory sequelae leading to re-hospitalisation</measure>
    <time_frame>2 years of age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to improve height development, psychomotor development and respiratory function</measure>
    <time_frame>7 years of age</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Infant, Premature, Diseases</condition>
  <condition>Respiratory Distress Syndrome, Newborn</condition>
  <condition>Bronchopulmonary Dysplasia</condition>
  <arm_group>
    <arm_group_label>Surfactant instillation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2.5 ml/kg of Surfactant will be instilled in the trachea</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo instillation</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2.5 ml/kg of Air will be instilled in the trachea</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Curosurf</intervention_name>
    <description>2.5 ml/kg instilled in the trachea</description>
    <arm_group_label>Surfactant instillation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Air</intervention_name>
    <description>2.5ml/kg of Air will be instilled in the trachea</description>
    <arm_group_label>Placebo instillation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  any neonate of gestational age less than 33 weeks of amenorrhea still on conventional
             assisted ventilation or HFOV (High Frequency Oscillatory Ventilation), after 14 Â± 2
             days of life

        Exclusion Criteria:

          -  active infection (CRP &gt; 30 mg/L) not controlled by appropriate antibiotic treatment

          -  use of corticosteroids in the postnatal period

          -  significant neurological or malformative disease

          -  surgical intervention &lt; 72 hours

          -  refusal of parental approval
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>16 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Michel HASCOET, MD</last_name>
    <role>Study Director</role>
    <affiliation>Maternite Regionale Universitaire NANCY</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Hopital Nord</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Angers</city>
        <zip>49033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>Arras</city>
        <zip>62000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Hopital Clemenceau</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU hopital d'enfants</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>Lens</city>
        <zip>62037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Hopital Jeanne de Flandre</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Hopital de la Croix Rousse</name>
      <address>
        <city>Lyon</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APHM hopital de la conception</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHI Andre Gregoire</name>
      <address>
        <city>Montreuil</city>
        <zip>93105</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maternite Regionale Universitaire</name>
      <address>
        <city>Nancy</city>
        <zip>54042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP Hopital Port Royal</name>
      <address>
        <city>Paris</city>
        <zip>75179</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Hopital Gatien de Clocheville</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 23, 2009</study_first_submitted>
  <study_first_submitted_qc>December 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2009</study_first_posted>
  <last_update_submitted>August 28, 2017</last_update_submitted>
  <last_update_submitted_qc>August 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Maternite Regionale Universitaire</investigator_affiliation>
    <investigator_full_name>Jean Michel Hascoet</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Very premature infant</keyword>
  <keyword>Surfactant</keyword>
  <keyword>Respiratory Distress</keyword>
  <keyword>Bronchopulmonary Dysplasia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Bronchopulmonary Dysplasia</mesh_term>
    <mesh_term>Infant, Premature, Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Surfactants</mesh_term>
    <mesh_term>Poractant alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

